4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (D-) Rating at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating reaffirmed by investment analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Several other research firms have also weighed in on FDMT. Bank of America lowered their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Chardan Capital reissued a “buy” rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Morgan Stanley lowered their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. Finally, Royal Bank of Canada reduced their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.56.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $5.93 on Friday. The company’s fifty day moving average price is $5.97 and its two-hundred day moving average price is $10.05. The firm has a market capitalization of $274.14 million, a PE ratio of -2.08 and a beta of 2.81. 4D Molecular Therapeutics has a 52-week low of $4.43 and a 52-week high of $36.25.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its stake in 4D Molecular Therapeutics by 25.5% in the second quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company’s stock valued at $398,000 after acquiring an additional 3,850 shares during the period. Algert Global LLC grew its position in shares of 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Algert Global LLC now owns 16,588 shares of the company’s stock valued at $348,000 after purchasing an additional 2,828 shares during the period. SG Americas Securities LLC bought a new stake in 4D Molecular Therapeutics during the 3rd quarter worth approximately $321,000. nVerses Capital LLC acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth approximately $40,000. Finally, Assenagon Asset Management S.A. lifted its stake in 4D Molecular Therapeutics by 238.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after buying an additional 1,087,147 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.